Vaxcell-Bio Therapeutics Co., Ltd. (KOSDAQ:323990)

South Korea flag South Korea · Delayed Price · Currency is KRW
9,120.00
-160.00 (-1.72%)
At close: Feb 27, 2026
-2.88%
Market Cap 212.11B
Revenue (ttm) n/a
Net Income (ttm) n/a
Shares Out 23.26M
EPS (ttm) n/a
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 276,257
Average Volume 349,353
Open 9,300.00
Previous Close 9,280.00
Day's Range 9,090.00 - 9,350.00
52-Week Range 6,970.00 - 12,670.00
Beta 0.97
RSI 42.14
Earnings Date Nov 11, 2025

About Vaxcell-Bio Therapeutics

Vaxcell-Bio Therapeutics Co., Ltd. develops and anticancer immunotherapy products in South Korea. The company was founded in 2010 and is headquartered in Hwasun-eup, South Korea. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2010
Country South Korea
Stock Exchange KOSDAQ
Ticker Symbol 323990
Full Company Profile

Financial Performance

In 2024, Vaxcell-Bio Therapeutics's revenue was 1.90 billion, an increase of 13737.28% compared to the previous year's 13.72 million. Losses were -10.62 billion, 3.40% more than in 2023.

Financial Statements

News

There is no news available yet.